Herrmann Edwin, Eltze Elke, Bierer Stefan, Köpke Thomas, Görge Tobias, Neumann Jorg, Hertle Lothar, Wülfing Christian
Department of Urology, University of Münster, Münster, Germany.
Anticancer Res. 2007 Sep-Oct;27(5A):3127-33.
Our aim was to determine the role of the lymphangiogenic markers VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer.
Archival cystectomy tumor blocks of 286 patients were selected for construction of a tissue microarray (TMA). Paraffin sections were assessed immunohistochemically using polyclonal antibodies against VEGF-C, VEGF-D and Flt-4. Staining results were evaluated semiquantitatively and analyzed for their association with various clinicopathological factors.
There was no association of VEGF-C with histopathological parameters or clinical outcome. Patients with VEGF-D overexpression had higher pathological tumor stages (p =0.021) and regional lymph node metastasis (p=0.008). Furthermore, they had a significantly reduced disease-free survival (p=0.042). Overexpression of Flt-4 was particularly present in the subgroup of G3 and G4 tumors (p=0.001) and was associated with a shorter disease-free survival (p=0.041). In multivariate analysis, only tumor stage and lymph node metastasis were independent prognostic parameters.
Targeting VEGF-D and Flt-4 could be a useful tool to predict and control progression of bladder cancer.
我们的目的是确定淋巴管生成标志物血管内皮生长因子C（VEGF-C）、血管内皮生长因子D（VEGF-D）和Flt-4在移行性膀胱癌中的作用。
选取286例患者的存档膀胱切除肿瘤组织块构建组织芯片（TMA）。石蜡切片采用抗VEGF-C、VEGF-D和Flt-4的多克隆抗体进行免疫组织化学评估。对染色结果进行半定量评估，并分析其与各种临床病理因素的相关性。
VEGF-C与组织病理学参数或临床结局无相关性。VEGF-D过表达的患者具有更高的病理肿瘤分期（p = 0.021）和区域淋巴结转移（p = 0.008）。此外，他们的无病生存期显著缩短（p = 0.042）。Flt-4的过表达尤其在G3和G4肿瘤亚组中出现（p = 0.001），并与较短的无病生存期相关（p = 0.041）。在多变量分析中，只有肿瘤分期和淋巴结转移是独立的预后参数。
靶向VEGF-D和Flt-4可能是预测和控制膀胱癌进展的有用工具。
